Veru Inc. (VERU)

Market Cap	98.81M
Revenue (ttm)	14.09M
Net Income (ttm)	-37.40M
Shares Out	146.38M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,035,115
Open	0.624
Previous Close	0.628
Day's Range	0.624 - 0.688
52-Week Range	0.360 - 1.920
Beta	-0.46
Analysts	Strong Buy
Price Target	4.00 (+492.59%)
Earnings Date	Dec 6, 2024

About VERU

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patient...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 1990
• Employees: 189
• Stock Exchange: NASDAQ
• Ticker Symbol: VERU
• Website: https://verupharma.com

Financial Performance

In 2023, Veru Inc.'s revenue was $16.30 million, a decrease of -58.59% compared to the previous year's $39.35 million. Losses were -$93.15 million, 10.8% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 492.59% from the latest price.

Price Target

$4.0

(492.59% upside)

Analyst Consensus: Strong Buy